AZD1390: Technical Guidance for ATM Kinase Inhibitor Use in Cancer Research

What This Product Solves

AZD1390 is a potent and selective inhibitor of the ataxia telangiectasia mutated (ATM) kinase, a core regulator of the DNA damage response following double-strand breaks. The compound enables researchers to dissect ATM signaling pathways and evaluate the effects of ATM inhibition on DNA repair, cell cycle control, and radiosensitization in cancer cell lines, particularly glioblastoma and lung cancer models. By blocking ATM activity, AZD1390 facilitates the study of DNA double-strand break repair inhibition and downstream cell fate decisions during genotoxic stress. It is especially relevant for experiments involving radiosensitization or investigation of checkpoint regulation in p53 mutant backgrounds. For those seeking an ATM kinase inhibitor with well-characterized selectivity and in vitro/in vivo applicability, AZD1390 provides a practical tool for focused research workflows. Product and workflow details are available from AZD1390 (APExBIO).

Protocol Parameters

Protocol Parameters

• assay: ATM kinase inhibition in cellular assays | value_with_unit: IC₅₀ = 0.78 nM | applicability: Determining effective dosing for ATM inhibition in cell-based systems | rationale: Guides initial concentration selection for ATM-dependent DNA damage response studies | source_type: product_spec [source_link: https://www.apexbt.com/azd1390.html]
• assay: Inhibition of ATM in glioblastoma LN18 cells | value_with_unit: 3 nM | applicability: Use as starting concentration for ATM blockade in glioblastoma cell lines | rationale: Supported by documented inhibition at this dose in product dossier | source_type: product_spec [source_link: https://www.apexbt.com/azd1390.html]
• assay: Radiosensitization in NCI-H2228 lung cancer cells (with radiation) | value_with_unit: 10 nM | applicability: Use for combination treatments with ionizing radiation in lung cancer model systems | rationale: Demonstrated efficacy for G2 arrest and apoptosis induction at this concentration | source_type: product_spec [source_link: https://www.apexbt.com/azd1390.html]
• assay: In vivo tumor growth inhibition (rat orthotopic lung-brain model, oral dosing) | value_with_unit: 20 mg/kg | applicability: Dosing regimen for animal studies assessing radiosensitization in brain/lung tumor models | rationale: Superior efficacy shown at this dose in product dossier | source_type: product_spec [source_link: https://www.apexbt.com/azd1390.html]
• assay: Compound solubility in DMSO | value_with_unit: ≥19.6 mg/mL | applicability: Preparation of concentrated stock solutions for in vitro or in vivo dosing | rationale: Ensures adequate solubilization before dilution into assay buffer or vehicle | source_type: product_spec [source_link: https://www.apexbt.com/azd1390.html]

Workflow Setup and QC Checklist

• Compound Handling: Store AZD1390 at -20°C in a desiccated environment to maintain ≥98% purity. Avoid repeated freeze-thaw cycles.
• Solution Preparation: Dissolve in DMSO to a stock concentration up to 19.6 mg/mL, using gentle warming and ultrasonic treatment as needed. For ethanol, do not exceed 3.04 mg/mL.
• Aliquoting: Prepare single-use aliquots to prevent compound degradation. Discard unused stock solutions after short-term use; long-term storage of solutions is not recommended.
• Assay Controls: Incorporate vehicle and untreated controls for all experimental arms. For radiosensitization, include radiation-only and AZD1390-only groups.
• Concentration Ranging: Establish a dose-response curve for new cell lines or models, starting at 0.5–10 nM for in vitro studies based on documented efficacy in LN18 and NCI-H2228 cells.
• Documentation: Record batch number, solubility observations, and storage conditions for full traceability.

Common Failure Modes and Fixes

• Poor Solubility: If AZD1390 does not fully dissolve in DMSO or ethanol, reapply gentle warming (below 40°C) and brief sonication. Do not use water as a solvent due to insolubility.
• Loss of Activity: Activity loss may result from repeated freeze-thaw cycles or prolonged storage of dissolved compound. Always use freshly prepared solutions and avoid storing working aliquots for more than 24 hours at room temperature or 1 week at -20°C.
• Assay Variability: Inconsistent cell responses may indicate batch-to-batch variation or poor stock solution quality. Always verify compound purity and confirm cell line identity and passage number.
• Non-specific Effects: If off-target toxicity is observed, reduce concentration or add additional controls (e.g., non-ATM dependent cell lines) to distinguish ATM-specific effects.

Scope and Limitations

• AZD1390 is optimized for ATM kinase inhibition in DNA double-strand break repair research and radiosensitization protocols in cancer cell lines and in vivo models. Its potency and selectivity are established for these applications only.
• The compound is not recommended for studies outside the DNA damage response or for exploring unrelated kinase pathways due to its selectivity profile.
• Solubility constraints limit its use in aqueous-only systems; always use DMSO or ethanol as a solvent, as described in the product dossier.
• Long-term storage of AZD1390 solutions is not supported; use freshly prepared working solutions for each experiment.
• For in vivo studies, animal dosing regimens must be validated and adjusted per protocol, starting from the recommended 20 mg/kg oral dose for lung-brain tumor models.

Conclusion

AZD1390 provides a robust, selective option for researchers investigating ATM kinase function, DNA double-strand break repair inhibition, and radiosensitization in cancer research. By following strict solubility, storage, and dosing guidelines, users can maximize data reliability while minimizing technical confounders. For further technical details, refer to the official AZD1390 product page (APExBIO).